Since 2009, AbbVie has provided compounds for DNDi to screen for activity against neglected diseases. Currently, AbbVie is working with DNDi to follow up on screening hits for parasites causing visceral leishmaniasis and Chagas’ disease, and nematodes causing river blindness and lymphatic filariasis. Promising compounds are entered into the AbbVie-DNDi collaboration agreement the provides DNDi a non-exclusive license to relevant AbbVie IP for use in the neglected diseases field. Any resulting products will be provided in endemic countries at the lowest sustainable price to expand patient access. AbbVie scientists also provide technical expertise to DNDi and participate as team members in DNDi discovery groups.
AbbVie also has a partnership with the Liverpool School of Tropical Medicine (LSTM) to help discover new macrofilaricides acting through an anti-Wolbachia mechanism. AbbVie is conducting the chemistry, DMPK, formulation and safety studies, and LSTM is conducting the in vitro anti-Wolbachia and animal efficacy screening.
|Location||Latin America and Caribbean, West Africa, Central Africa, Central Asia, Eastern Africa, North Africa and Middle East, South Asia, Southern Africa|